The Secretary
The National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G. Block
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Secretary
The Calcutta Stock Exchange Limited
7, Lyons Range
Kolkata - 700001

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

Dear Sirs,
Pursuant to Provision of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of Presentation on Company's Overview.

The aforesaid information is also given on the website of the company www.emamiltd.in

This is for your information and records.

Thanking you,

Yours faithfully,
For Emami Limited

Ashok Purohit
Assistant Company Secretary
(Encl. : As above)

emamî limited

## Q2 \& H1FY21

## Revenues

| Key Financials | Q2FY21 <br> Growth | H1FY21 <br> Growth |
| :--- | :---: | :---: |
| - Domestic Business | $13 \%$ | $-7 \%$ |
| - International Business | $11 \%$ | $-4 \%$ |
| - Institutional Business | $-2 \%$ | $-21 \%$ |
| Consolidated Net Sales | $12 \%$ | $-\mathbf{- 7 \%}$ |
| - Other Operating Income | $-39 \%$ | $-28 \%$ |
| Total Revenues | $\mathbf{1 1 \%}$ | $\mathbf{- 7 \%}$ |

Q2FY21 Business Wise Sales Split
Institutional

Int'I
Business 17\%

- $10 \%$ volume growth in Domestic Business


## Q2FY21 Profitability

 (Consolidated)| Key Financials | Q2FY21 <br> Growth | Margins | Margin Growth |
| :--- | :---: | :---: | :---: |
| Revenues | $11 \%$ | - | - |
| Gross Profit | $12 \%$ | $70.3 \%$ | +60 bps |
| EBIDTA | $33 \%$ | $35.0 \%$ | +570 bps |
| PAT | $23 \%$ | $16.1 \%$ | +160 bps |
| Cash Profit | $31 \%$ | $31.7 \%$ | +480 bps |

- Margins increased due to stringent cost control measures and benign raw material prices.

Q2FY21

## Domestic Portfolio Snapshot



## Winter Portfolio



Vasocare ${ }^{\text {B }}$


## Domestic Performance

## $+28 \%$

Domestic Business Growth excl. Winter Portfolio in Q2FY21 ( c. 88\%)


Achieved for Kesh King and Pain Management Range <br> \title{
Highest <br> \title{
Highest Quarterly Sales
}


## New Launches

## in Q2FY21 - Hygiene \& Healthcare




Giloy Ghana Vati


Giloy Churna


Zandu Amla Churna


Zandu Immuzan Tab (Ethical)


Zandu Rhumasyl Maxx (Ethical)

## New Launches

Performance


New launches in H1FY21

SKU's launched in H1FY21

4\%
Contribution to Domestic Business
(in Q2 \& H1)


## Q2FY21 Domestic

## Brandwise Performance

| Key Brands | Q2FY21 Growth | H1FY21 Growth |
| :--- | :---: | :---: |
| Healthcare Range | $53 \%$ | $40 \%$ |
| Pain Management Range | $31 \%$ | $25 \%$ |
| Navratna Range | $14 \%$ | $-25 \%$ |
| Kesh King Range | $45 \%$ | $2 \%$ |
| BoroPlus Range | $-25 \%$ | $-16 \%$ |
| Male Grooming Range | $-24 \%$ | $-51 \%$ |
| 7 Oils in One | $9 \%$ | $-16 \%$ |
|  |  |  |
| $-\quad$ H1FY21 Secondary Sales almost at par with PY |  |  |
| Sequential recovery witnessed in Fair and Handsome since August'20 |  |  |

ZANDU Launch of

## care <br> E-Commerce Portal

## FREE

 SHIPPING
## ON ALL ORDERS

蜔 No minimum order value
$\{\%$ Limited period offer

- Launched own e-commerce portal-www.zanducare.com
- A brand store for Zandu Healthcare products
- Catering existing products as well as newly launched e-commerce specific products.


## International Business <br> Performance

. Sales grew by $11 \%$ in Q 2 restricting the decline to $4 \%$ in H1FY21

- Q2FY21 Sales performance-
- SAARC grew by $22 \%$
- MENAP grew by $12 \%$
- 7 Oils in One becomes the largest selling brand for International Business.


[^0]
## New Launches - <br> International Business

## Creme 21 Range


 Bollywood celebrity Juhi Chawla Campaign to promote trials


New TVC for Zandu Ayurvedic Cough Syrup to continue relevance in COVID environment


New TVC campaign for Zandu Pancharishta establishing the link of Digestion and Immunity
 Navratna driving relevance in COVID environment

## Print \& Digital <br> Campaigns




Q2FY21

## Financial Analysis



## Financial Analysis



## Summarized Financials

₹ in Millions

| Particulars | Q2FY21 | \% | 02FY20 | \% | Growth \% | FY20 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 7,277.9 | 99.0\% | 6,486.2 | 98.3\% | 12.2\% | 26,106.4 | 98.3\% |
| Other Operating Income | 70.3 | 1.0\% | 114.3 | 1.7\% | -38.5\% | 442.4 | 1.7\% |
| Revenue from Operations | 7,348.2 | 100.0\% | 6,600.5 | 100.0\% | 11.3\% | 26,548.8 | 100.0\% |
| Materials Cost | 2,184.8 | 29.7\% | 1,998.8 | 30.3\% | 9.3\% | 8,761.0 | 33.0\% |
| A\&P | 1,080.8 | 14.7\% | 1,049.2 | 15.9\% | 3.0\% | 4,711.4 | 17.7\% |
| Staff Cost | 783.8 | 10.7\% | 753.1 | 11.4\% | 4.1\% | 2,995.1 | 11.3\% |
| Admn \& Other Exp | 727.9 | 9.9\% | 869.6 | 13.2\% | -16.3\% | 3,175.9 | 12.0\% |
| EBIDTA | 2,570.9 | 35.0\% | 1,929.8 | 29.2\% | 33.2\% | 6,905.4 | 26.0\% |
| Other Income | 78.9 | 1.1\% | 163.8 | 2.5\% | -51.8\% | 570.7 | 2.1\% |
| Interest | 24.8 | 0.3\% | 93.2 | 1.4\% | -73.4\% | 210.1 | 0.8\% |
| Amortisation of acquired TM's/brands | 932.2 | 12.7\% | 640.6 | 9.7\% | 45.5\% | 2,589.0 | 9.8\% |
| Depreciation/Amortisation of other assets | 216.1 | 2.9\% | 178.1 | 2.7\% | 21.3\% | 774.3 | 2.9\% |
| PBT before Exceptional Items | 1,476.7 | 20.1\% | 1,181.7 | 17.9\% | 25.0\% | 3,902.7 | 14.7\% |
| Exceptional Items | - | 0.0\% | - | 0.0\% | 0.0\% | 106.8 | 0.4\% |
| PBT | 1,476.7 | 20.1\% | 1,181.7 | 17.9\% | 25.0\% | 3,795.9 | 14.3\% |
| Tax | 284.0 | 3.9\% | 211.3 | 3.2\% | 34.4\% | 712.7 | 2.7\% |
| PAT | 1,192.7 | 16.2\% | 970.4 | 14.7\% | 22.9\% | 3,083.2 | 11.6\% |
| Share of Minority Interest \& P/L of Associate | [8.5) | -0.1\% | (10.4) | -0.2\% | -18.3\% | [54.1) | -0.2\% |
| PAT After Minority Interest \& Associate | 1,184.2 | 16.1\% | 960.0 | 14.5\% | 23.4\% | 3,029.1 | 11.4\% |
| Cash Profit (PAT + Dep. \& Amortization) | 2,332.5 | 31.7\% | 1,778.7 | 26.9\% | 31.1\% | 6,392.4 | 24.1\% |
| EPS - Rs. | 2.66 |  | 2.12 |  |  | 6.67 |  |
| Cash EPS-Rs. | 5.25 |  | 3.92 |  |  | 14.08 |  |

The useful life of Intangible assets related to acquired Brands and Trademarks, revised from 10 years to 7 years resulting in an increase in amortisation by ₹ 663 mn in Q2FY21

## Summarized Financials

| Particulars | H1FY21 | \% | H1FY20 | \% | Growth \% | FY20 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 12,006.1 | 98.7\% | 12,880.1 | 98.4\% | -6.8\% | 26,106.4 | 98.3\% |
| Other Operating Income | 155.5 | 1.3\% | 215.5 | 1.6\% | -27.8\% | 442.4 | 1.7\% |
| Revenue from Operations | 12,161.6 | 100.0\% | 13,095.6 | 100.0\% | -7.1\% | 26,548.8 | 100.0\% |
| Materials Cost | 3,798.2 | 31.2\% | 4,323.1 | 33.0\% | -12.1\% | 8,761.0 | 33.0\% |
| A\&P | 1,677.9 | 13.8\% | 2,339.7 | 17.9\% | -28.3\% | 4,711.4 | 17.7\% |
| Staff Cost | 1,565.1 | 12.9\% | 1,525.9 | 11.7\% | 2.6\% | 2,995.1 | 11.3\% |
| Admn \& Other Exp | 1,319.7 | 10.9\% | 1,627.0 | 12.4\% | -18.9\% | 3,175.9 | 12.0\% |
| EBIDTA | 3,800.7 | 31.3\% | 3,279.9 | 25.0\% | 15.9\% | 6,905.4 | 26.0\% |
| Other Income | 145.9 | 1.2\% | 270.0 | 2.1\% | -46.0\% | 570.7 | 2.1\% |
| Interest | 71.8 | 0.6\% | 136.7 | 1.0\% | -47.5\% | 210.1 | 0.8\% |
| Amortisation of acquired TM's/ brands | 1,486.5 | 12.2\% | 1,314.4 | 10.0\% | 13.1\% | 2,589.0 | 9.8\% |
| Depreciation/Amortisation of other assets | 409.7 | 3.4\% | 341.0 | 2.6\% | 20.1\% | 774.3 | 2.9\% |
| PBT before Exceptional Items | 1,978.6 | 16.3\% | 1,757.8 | 13.4\% | 12.6\% | 3,902.7 | 14.7\% |
| Exceptional Items | - | 0.0\% | - | 0.0\% | 0.0\% | 106.8 | 0.4\% |
| PBT | 1,978.6 | 16.3\% | 1,757.8 | 13.4\% | 12.6\% | 3,795.9 | 14.3\% |
| Tax | 378.8 | 3.1\% | 388.2 | 3.0\% | -2.4\% | 712.7 | 2.7\% |
| PAT | 1,599.8 | 13.2\% | 1,369.6 | 10.5\% | 16.8\% | 3,083.2 | 11.6\% |
| Share of Minority Interest \& P/L of Associate | (19.6) | -0.2\% | (17.0) | -0.1\% | 15.3\% | [54.1) | -0.2\% |
| PAT After Minority Interest \& Associate | 1,580.2 | 13.0\% | 1,352.6 | 10.3\% | 16.8\% | 3,029.1 | 11.4\% |
| Cash Profit (PAT + Dep. \& Amortization) | 3,476.4 | 28.6\% | 3,008.0 | 23.0\% | 15.6\% | 6,392.4 | 24.1\% |
| EPS - Rs. | 3.55 |  | 2.98 |  |  | 6.67 |  |
| Cash EPS-Rs. | 7.79 |  | 6.63 |  |  | 14.08 |  |

## Balance Sheet

₹ in Millions
\&nam*


## Q2 Performance at a glance

$\triangleright$ Double digit volume growth in Domestic business. 28\% growth excluding winter portfolio

- H1FY21 Secondary Sales almost at par with PY due to strong growth in Q2FY21
- Growth across all channels -MT back to growth; E commerce tripled revenues
- Highest ever quarterly sales registered for Kesh King and Pain Management range
- Growth across most of the power brands. Healthcare range grew by 53\%
- Sequential recovery witnessed in Fair and Handsome since August'20
$\triangleright 20$ new products and 40+ SKU's launched in H1FY21. Contributed 4\% to Domestic sales
$\triangleright$ Launched online brand store for Zandu Healthcare products - www.zanducare.com
- International Business also grew in double digits
- Strong profit led growth.
- Margins increased due to stringent cost control measures and benign raw material prices.
- Net Cash of ₹ 250 cr after spending ₹ 237 cr on Buyback of shares.
$\triangleright$ Board of Directors declared Interim Dividend at 400\% i.e. Rs. 4/- per equity share

Thank you


[^0]:    SAARC South Asian Association for Regional Cooperation (Major countries - Bangladesh, Nepal, Sri Lanka etc.]

